Argos Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
Argos Therapeutics Inc. (Nasdaq: ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company has been added to the Russell 2000® Index and the Russell 3000® Index. The addition is effective as of March 31, 2014.
The Russell 2000® Index measures the performance of the small-cap U.S. equity market. It is a subset of the Russell 3000® Index, representing approximately 10% of the total market capitalization of that index. Companies are ranked based on a combination of their market cap and current index membership.
"We are very pleased that Argos has been added to the portfolio of companies included in the Russell 2000® and Russell 3000® indexes, positioning us for broader visibility in the investment community. As we work aggressively to advance our clinical research programs, we will continue to take steps to enhance both our visibility and our attractiveness to investors as we move forward," said Jeff Abbey, president and chief executive officer of Argos Therapeutics.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.